par Soubhye, Jalal 
;Furtmueller, Paul G;Dufrasne, François ;Obinger, Christian
Editeur scientifique Schmidt, Harald H.H.H.W.;Ghezzi,
Référence Inhibition of Myeloperoxidase, Springer, Cham, Switzerland, Vol. 264, Ed. 1, Reactive oxygen species, page (261-285)
Publication Publié, 2021-01-01
;Furtmueller, Paul G;Dufrasne, François ;Obinger, ChristianEditeur scientifique Schmidt, Harald H.H.H.W.;Ghezzi,
Référence Inhibition of Myeloperoxidase, Springer, Cham, Switzerland, Vol. 264, Ed. 1, Reactive oxygen species, page (261-285)
Publication Publié, 2021-01-01
Partie d'ouvrage collectif
| Résumé : | Myeloperoxidase participates in innate immune defense mechanism through formation of microbicidal reactive oxidants and diffusible radical species. A unique activity is its ability to use chloride as a cosubstrate with hydrogen peroxide to generate chlorinating oxidants such as hypochlorous acid, a potent antimicrobial agent. However, chronic MPO activation can lead to indiscriminate protein modification causing tissue damage, and has been associated with chronic inflammatory diseases, atherosclerosis, and acute cardiovascular events. This has attracted considerable interest in the development of therapeutically useful MPO inhibitors. Today, based on the profound knowledge of structure and function of MPO and its biochemical and biophysical differences with the other homologous human peroxidases, various rational and high-throughput screening attempts were performed in developing specific irreversible and reversible inhibitors. The most prominent candidates as well as MPO inhibitors already studied in clinical trials are introduced and discussed. |
